Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease

Summary.  The cell surface proteins CD20 and CD52 differ significantly in their structures and are expressed on the majority of B cells. Both circulating CD20 (cCD20) and circulating CD52 (cCD52) have been recently documented in patients with chronic lymphocytic leukaemia. A retrospective study to establish whether cCD20 and/or cCD52 were detectable in patients with lymphoma, and the clinical associations of these soluble antigens if detected, was conducted. cCD20 and cCD52 levels were analysed in a cohort of 65 patients with non‐Hodgkin's lymphoma (NHL) and 37 with Hodgkin's disease (HD). Patients with NHL had elevated pretherapy levels of cCD20 and cCD52 compared with normal individuals. Patients with HD had significantly lower than normal pretherapy levels of both cCD20 and cCD52. cCD20 levels were marginally elevated post‐therapy in NHL patients while in patients with HD, cCD20 levels remained significantly lower than normal after therapy. Serum cCD52 levels became significantly lower than normal post‐therapy in NHL patients, and remained significantly lower than normal in HD patients. No predictive effects were found for pretherapy or post‐therapy levels of cCD52 on survival for either cohort of patients. Post‐therapy cCD20 levels independently highly correlated with survival in patients with NHL. Prospective evaluation will be required to establish if cCD20 and cCD52 may be used as biomarkers in the diagnosis, prognostic categorization, and monitoring of the clinical course in patients with lymphoma. The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study.

[1]  G. Weiner,et al.  Monoclonal antibody therapy of B cell lymphoma , 2004, Expert opinion on biological therapy.

[2]  K. Do,et al.  Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. , 2003, Blood.

[3]  D. Podoloff,et al.  Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  K. Do,et al.  Circulating CD 20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance , 2003 .

[5]  Nils Lid Hjort,et al.  Goodness‐of‐fit processes for logistic regression: simulation results , 2002, Statistics in medicine.

[6]  M. Keating,et al.  Emerging information on the use of rituximab in chronic lymphocytic leukemia. , 2002, Seminars in oncology.

[7]  W. Wilson,et al.  The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. , 2002, Seminars in oncology.

[8]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[9]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[10]  U. Jaeger,et al.  Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[11]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A Domagała,et al.  CD52 antigen--a review. , 2001, Medical science monitor : international medical journal of experimental and clinical research.

[13]  M. Sliwkowski,et al.  CD20: a gene in search of a function. , 2000, Seminars in oncology.

[14]  S. O'brien,et al.  High-dose rituximab therapy in chronic lymphocytic leukemia. , 2000, Seminars in oncology.

[15]  P. Mclaughlin,et al.  Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. , 2000, Seminars in oncology.

[16]  C. Kirchhoff,et al.  New Insights into the Origin, Structure and Role of CD52: A Major Component of the Mammalian Sperm Glycocalyx , 2000, Cells Tissues Organs.

[17]  B. Harms,et al.  CD52 mRNA is modulated by androgens and temperature in epididymal cell cultures , 2000, Molecular reproduction and development.

[18]  J. K. Hofmeister,et al.  Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. , 2000, Blood cells, molecules & diseases.

[19]  Zhensheng Liu,et al.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.

[20]  M. C. Liu,et al.  Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. , 2000, Clinical immunology.

[21]  H. Waldmann,et al.  Structure and chromosomal location of mouse and human CD52 genes. , 1999, Biochimica et biophysica acta.

[22]  W. Rowan,et al.  Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells , 1998, Immunology.

[23]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Johnson,et al.  The association between CD20 and Src-family Tyrosine kinases requires an additional factor. , 1998, Molecular Immunology.

[25]  L. Ginaldi,et al.  Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. , 1998, Leukemia research.

[26]  S. Robbins,et al.  Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment* , 1998, The Journal of Biological Chemistry.

[27]  K. Spiekermann,et al.  Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. , 1996, Blood.

[28]  G. Schieven,et al.  Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20 , 1995, The Journal of Biological Chemistry.

[29]  J Hermans,et al.  International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. , 1995, Blood.

[30]  T. Tedder,et al.  CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.

[31]  G. L. Wilson,et al.  Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. , 1994, Immunology today.

[32]  M. Ferguson,et al.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. , 1993, The Biochemical journal.

[33]  T. Tedder,et al.  Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. , 1988, The Journal of biological chemistry.

[34]  E. Clark,et al.  The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. , 1985, Journal of immunology.

[35]  D.,et al.  Regression Models and Life-Tables , 2022 .